You are here: Industry Insights > Cobra Biologics

News List

Cobra Biologics and CombiGene Partner contractpharma
September 24, 2020
Sign agreement to secure GMP production of plasmids for production of CG01 gene therapy.
Cobra Produces Master Cell Banks for CombiGene’s Gene Therapy contractpharma
August 19, 2020
A milestone in the manufacture of a drug candidate for the treatment of focal epilepsy.
Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate contractpharma
July 14, 2020
Completes delivery of all plasmids required to progress to the next phase of the project.
Cobra Biologics Completes Key CombiGene Milestone contractpharma
April 06, 2020
Successfully produced and delivered the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate.
Cobra Biologics Joins COVID-19 Consortium contractpharma
April 01, 2020
Aims to rapidly develop, scale-up and produce potential adenoviral vaccine candidate for COVID-19.
Cobra Bio, Karolinska Inst. to Develop COVID-19 Vaccine contractpharma
March 31, 2020
Cobra Biologics, an international contract development and manufacturing organization (CDMO) for biologics and pharmaceuticals, and the Karolinska Institutet ...
Grant winners to investigate continuous manufacturing for gene therapies cphi-online
November 27, 2018
Cobra Biologics has won a £1.5 million shared grant from Innovate UK, the UK’s innovation agency. Co-winners, Pall Corporation, a global leader in filtration, separation and purification
Three-way collaboration to advance gene therapy cphi-online
November 15, 2018
Cobra Biologics is to collaborate with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way partnership
Three-way collaboration to advance gene therap cphi-online
November 14, 2018
Cobra Biologics is to collaborate with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way partnership
Cobra Biologics Awarded $3.4M by Innovate UK contractpharma
January 31, 2018
Cobra Biologics has been awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK.

Previous page 1 2 Next page